BTOG News & NICE News
BTOG News
Statement on the UK Tobacco and Vapes Bill
The UK Tobacco and Vapes Bill represents a landmark moment in tobacco control, positioning the UK as a global leader in efforts to reduce...
BTOG Unveils a Refreshed Logo Reflecting a Modern, Unified Identity
BTOG has refreshed its logo to reflect who we are today - a connected, forward-thinking community dedicated to improving outcomes for people with...
BTOG Responds to Government’s 10-Year National Cancer Plan for England
BTOG has published its formal response to the UK Government’s newly announced 10-Year National Cancer Plan for England, welcoming its ambition while...
NICE News
Amivantamab with carboplatin and pemetrexed during the managed access period as an option for untreated advanced NSCLC with activating ex20ins mutations in adults
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended amivantamab with carboplatin and...
Osimertinib for maintenance treatment of EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended osimertinib, within its marketing...
Encorafenib plus binimetinib as an option to treat BRAF V600E mutation-positive advanced NSCLC
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended encorafenib plus binimetinib as an...